FDA Meeting Dives into New Cancer Drug Approvals
Published Date: 5/8/2025
Notice
Summary
The FDA is holding a public meeting to talk about new and updated cancer drugs, including COLUMVI, DARZALEX FASPRO, mitomycin solution, and TALZENNA capsules. This meeting affects patients, doctors, and drug makers by reviewing important changes that could impact treatment options and costs. The FDA also wants your comments before making final decisions, so now’s the time to speak up!
Analyzed Economic Effects
1 provisions identified: 0 benefits, 0 costs, 1 mixed.
FDA Reviews Cancer Drug Applications
The FDA will hold a public Oncologic Drugs Advisory Committee meeting to review applications for COLUMVI (glofitamab) S-001, DARZALEX FASPRO (daratumumab and hyaluronidase) S-029, new drug application 215793 for mitomycin intravesical solution, and supplemental NDA 211651/S-013 for TALZENNA (talazoparib) capsules. The meeting reviews changes that the document says could affect patients, doctors, and drug makers by influencing treatment options and costs. FDA is establishing a public docket and requesting comments before making final recommendations.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16959, Frequently Asked Questions-Developing Potential Cellular and Gene Therapy Products; Final Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance titled "Frequently asked Questions--Developing Potential Cellular and Gene Therapy Products." The guidance document provides industry with answers to frequently asked questions (FAQs) and commonly faced issues that arise during the development of cellular and gene therapy (CGT) products. The FAQs represent common questions directed to the Agency and span multiple disciplines, including regulatory review; chemistry, manufacturing, and controls (CMC); pharmacology/toxicology; clinical; and clinical pharmacology. This guidance announced in this notice finalizes the draft guidance of the same title issued on November 19, 2024.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
Previous / Next Documents
Previous: 2025-08059, Agency Information Collection Activities; Proposed eCollection eComments Requested; Extension of a Previously Approved Collection; National Use-of-Force Data Collection
The FBI is asking to keep collecting data about how police use force, making sure the info stays accurate and up-to-date. This affects law enforcement agencies across the country, helping everyone understand and improve safety. They’re asking for approval to continue this work, with no new costs or big changes, so the process stays smooth and reliable.
Next: 2025-08061, Combined Notice of Filings #1
The Federal Energy Regulatory Commission got a bunch of new filings from energy companies about their status and rates. This affects companies like AE-ESS Holyoke, Cascade BESS, and Duke Energy Florida, with some changes possibly impacting costs starting as soon as May 1, 2025. If you want to comment or keep an eye on these updates, deadlines are mostly in mid to late May.